(CHE) Chemed - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US16359R1032
Stock: Healthcare, Plumbing, Restoration
Total Rating 33
Risk 85
Buy Signal -0.80
| Risk 5d forecast | |
|---|---|
| Volatility | 27.5% |
| Relative Tail Risk | -14.6% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.10 |
| Alpha | -38.57 |
| Character TTM | |
|---|---|
| Beta | 0.265 |
| Beta Downside | 0.237 |
| Drawdowns 3y | |
|---|---|
| Max DD | 38.54% |
| CAGR/Max DD | -0.17 |
EPS (Earnings per Share)
Revenue
Description: CHE Chemed March 04, 2026
Chemed Corporation (CHE) operates in two distinct segments: healthcare and plumbing/drainage.
The VITAS segment provides hospice and palliative care, utilizing a team of medical professionals and support staff. This business model focuses on end-of-life care, a specialized area within healthcare services.
The Roto-Rooter segment offers plumbing, drain cleaning, and water restoration services to both residential and commercial clients. This segment operates through a combination of company-owned branches, independent contractors, and franchisees, a common structure in service industries.
For more detailed analysis, consider exploring ValueRays comprehensive reports.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 265.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.21 > 0.02 and ΔFCF/TA -0.89 > 1.0 |
| NWC/Revenue: 0.61% < 20% (prev 4.49%; Δ -3.87% < -1%) |
| CFO/TA 0.25 > 3% & CFO 388.3m > Net Income 265.2m |
| Net Debt (69.2m) to EBITDA (423.9m): 0.16 < 3 |
| Current Ratio: 1.05 > 1.5 & < 3 |
| Outstanding Shares: last quarter (14.0m) vs 12m ago -6.66% < -2% |
| Gross Margin: 31.14% > 18% (prev 0.35%; Δ 3079 % > 0.5%) |
| Asset Turnover: 157.8% > 50% (prev 145.7%; Δ 12.08% > 0%) |
| Interest Coverage Ratio: 109.0 > 6 (EBITDA TTM 423.9m / Interest Expense TTM 3.29m) |
Altman Z'' 5.49
| A: 0.01 (Total Current Assets 302.6m - Total Current Liabilities 287.1m) / Total Assets 1.54b |
| B: 0.64 (Retained Earnings 979.4m / Total Assets 1.54b) |
| C: 0.22 (EBIT TTM 359.1m / Avg Total Assets 1.60b) |
| D: 1.75 (Book Value of Equity 979.4m / Total Liabilities 558.8m) |
| Altman-Z'' Score: 5.49 = AAA |
Beneish M -2.78
| DSRI: 1.03 (Receivables 182.6m/171.2m, Revenue 2.53b/2.43b) |
| GMI: 1.13 (GM 31.14% / 35.14%) |
| AQI: 1.27 (AQ_t 0.72 / AQ_t-1 0.57) |
| SGI: 1.04 (Revenue 2.53b / 2.43b) |
| TATA: -0.08 (NI 265.2m - CFO 388.3m) / TA 1.54b) |
| Beneish M-Score: -2.78 (Cap -4..+1) = A |
What is the price of CHE shares?
As of March 07, 2026, the stock is trading at USD 407.88 with a total of 291,509 shares traded.
Over the past week, the price has changed by -0.52%, over one month by -8.79%, over three months by -1.00% and over the past year by -31.04%.
Over the past week, the price has changed by -0.52%, over one month by -8.79%, over three months by -1.00% and over the past year by -31.04%.
Is CHE a buy, sell or hold?
Chemed has received a consensus analysts rating of 4.67.
Therefore, it is recommended to buy CHE.
- StrongBuy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CHE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 443 | 8.6% |
| Analysts Target Price | 443 | 8.6% |
CHE Fundamental Data Overview March 03, 2026
P/E Trailing = 21.6937
P/E Forward = 16.2075
P/S = 2.3615
P/B = 5.3728
P/EG = 1.62
Revenue TTM = 2.53b USD
EBIT TTM = 359.1m USD
EBITDA TTM = 423.9m USD
Long Term Debt = 102.9m USD (estimated: total debt 143.8m - short term 40.9m)
Short Term Debt = 40.9m USD (from shortTermDebt, last quarter)
Debt = 143.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 69.2m USD (from netDebt column, last quarter)
Enterprise Value = 6.04b USD (5.97b + Debt 143.8m - CCE 74.5m)
Interest Coverage Ratio = 109.0 (Ebit TTM 359.1m / Interest Expense TTM 3.29m)
EV/FCF = 18.57x (Enterprise Value 6.04b / FCF TTM 325.5m)
FCF Yield = 5.39% (FCF TTM 325.5m / Enterprise Value 6.04b)
FCF Margin = 12.86% (FCF TTM 325.5m / Revenue TTM 2.53b)
Net Margin = 10.48% (Net Income TTM 265.2m / Revenue TTM 2.53b)
Gross Margin = 31.14% ((Revenue TTM 2.53b - Cost of Revenue TTM 1.74b) / Revenue TTM)
Gross Margin QoQ = 32.22% (prev 28.91%)
Tobins Q-Ratio = 3.93 (Enterprise Value 6.04b / Total Assets 1.54b)
Interest Expense / Debt = 0.36% (Interest Expense 521.0k / Debt 143.8m)
Taxrate = 27.21% (28.7m / 105.4m)
NOPAT = 261.4m (EBIT 359.1m * (1 - 27.21%))
Current Ratio = 1.05 (Total Current Assets 302.6m / Total Current Liabilities 287.1m)
Debt / Equity = 0.15 (Debt 143.8m / totalStockholderEquity, last quarter 979.4m)
Debt / EBITDA = 0.16 (Net Debt 69.2m / EBITDA 423.9m)
Debt / FCF = 0.21 (Net Debt 69.2m / FCF TTM 325.5m)
Total Stockholder Equity = 1.11b (last 4 quarters mean from totalStockholderEquity)
RoA = 16.54% (Net Income 265.2m / Total Assets 1.54b)
RoE = 23.92% (Net Income TTM 265.2m / Total Stockholder Equity 1.11b)
RoCE = 29.63% (EBIT 359.1m / Capital Employed (Equity 1.11b + L.T.Debt 102.9m))
RoIC = 22.68% (NOPAT 261.4m / Invested Capital 1.15b)
WACC = 6.73% (E(5.97b)/V(6.12b) * Re(6.89%) + D(143.8m)/V(6.12b) * Rd(0.36%) * (1-Tc(0.27)))
Discount Rate = 6.89% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -4.27%
[DCF] Terminal Value 84.05% ; FCFF base≈342.5m ; Y1≈377.6m ; Y5≈486.0m
[DCF] Fair Price = 789.1 (EV 11.20b - Net Debt 69.2m = Equity 11.13b / Shares 14.1m; r=6.73% [WACC]; 5y FCF grow 11.79% → 2.90% )
EPS Correlation: 41.38 | EPS CAGR: 8.12% | SUE: -1.01 | # QB: 0
Revenue Correlation: 96.05 | Revenue CAGR: 5.10% | SUE: -4.0 | # QB: 0
EPS next Quarter (2026-06-30): EPS=5.39 | Chg7d=-0.497 | Chg30d=-0.497 | Revisions Net=-2 | Analysts=4
EPS current Year (2026-12-31): EPS=24.01 | Chg7d=-1.400 | Chg30d=-1.400 | Revisions Net=-1 | Growth EPS=+11.4% | Growth Revenue=+5.5%
EPS next Year (2027-12-31): EPS=26.83 | Chg7d=-0.553 | Chg30d=-0.553 | Revisions Net=-1 | Growth EPS=+11.8% | Growth Revenue=+6.2%
[Analyst] Revisions Ratio: -1.00 (0 Up / 2 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.3% (Discount Rate 7.9% - Earnings Yield 4.6%)
[Growth] Growth Spread = +3.3% (Analyst 6.7% - Implied 3.3%)
P/E Forward = 16.2075
P/S = 2.3615
P/B = 5.3728
P/EG = 1.62
Revenue TTM = 2.53b USD
EBIT TTM = 359.1m USD
EBITDA TTM = 423.9m USD
Long Term Debt = 102.9m USD (estimated: total debt 143.8m - short term 40.9m)
Short Term Debt = 40.9m USD (from shortTermDebt, last quarter)
Debt = 143.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 69.2m USD (from netDebt column, last quarter)
Enterprise Value = 6.04b USD (5.97b + Debt 143.8m - CCE 74.5m)
Interest Coverage Ratio = 109.0 (Ebit TTM 359.1m / Interest Expense TTM 3.29m)
EV/FCF = 18.57x (Enterprise Value 6.04b / FCF TTM 325.5m)
FCF Yield = 5.39% (FCF TTM 325.5m / Enterprise Value 6.04b)
FCF Margin = 12.86% (FCF TTM 325.5m / Revenue TTM 2.53b)
Net Margin = 10.48% (Net Income TTM 265.2m / Revenue TTM 2.53b)
Gross Margin = 31.14% ((Revenue TTM 2.53b - Cost of Revenue TTM 1.74b) / Revenue TTM)
Gross Margin QoQ = 32.22% (prev 28.91%)
Tobins Q-Ratio = 3.93 (Enterprise Value 6.04b / Total Assets 1.54b)
Interest Expense / Debt = 0.36% (Interest Expense 521.0k / Debt 143.8m)
Taxrate = 27.21% (28.7m / 105.4m)
NOPAT = 261.4m (EBIT 359.1m * (1 - 27.21%))
Current Ratio = 1.05 (Total Current Assets 302.6m / Total Current Liabilities 287.1m)
Debt / Equity = 0.15 (Debt 143.8m / totalStockholderEquity, last quarter 979.4m)
Debt / EBITDA = 0.16 (Net Debt 69.2m / EBITDA 423.9m)
Debt / FCF = 0.21 (Net Debt 69.2m / FCF TTM 325.5m)
Total Stockholder Equity = 1.11b (last 4 quarters mean from totalStockholderEquity)
RoA = 16.54% (Net Income 265.2m / Total Assets 1.54b)
RoE = 23.92% (Net Income TTM 265.2m / Total Stockholder Equity 1.11b)
RoCE = 29.63% (EBIT 359.1m / Capital Employed (Equity 1.11b + L.T.Debt 102.9m))
RoIC = 22.68% (NOPAT 261.4m / Invested Capital 1.15b)
WACC = 6.73% (E(5.97b)/V(6.12b) * Re(6.89%) + D(143.8m)/V(6.12b) * Rd(0.36%) * (1-Tc(0.27)))
Discount Rate = 6.89% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -4.27%
[DCF] Terminal Value 84.05% ; FCFF base≈342.5m ; Y1≈377.6m ; Y5≈486.0m
[DCF] Fair Price = 789.1 (EV 11.20b - Net Debt 69.2m = Equity 11.13b / Shares 14.1m; r=6.73% [WACC]; 5y FCF grow 11.79% → 2.90% )
EPS Correlation: 41.38 | EPS CAGR: 8.12% | SUE: -1.01 | # QB: 0
Revenue Correlation: 96.05 | Revenue CAGR: 5.10% | SUE: -4.0 | # QB: 0
EPS next Quarter (2026-06-30): EPS=5.39 | Chg7d=-0.497 | Chg30d=-0.497 | Revisions Net=-2 | Analysts=4
EPS current Year (2026-12-31): EPS=24.01 | Chg7d=-1.400 | Chg30d=-1.400 | Revisions Net=-1 | Growth EPS=+11.4% | Growth Revenue=+5.5%
EPS next Year (2027-12-31): EPS=26.83 | Chg7d=-0.553 | Chg30d=-0.553 | Revisions Net=-1 | Growth EPS=+11.8% | Growth Revenue=+6.2%
[Analyst] Revisions Ratio: -1.00 (0 Up / 2 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.3% (Discount Rate 7.9% - Earnings Yield 4.6%)
[Growth] Growth Spread = +3.3% (Analyst 6.7% - Implied 3.3%)